Ribociclib: Difference between revisions

Revision as of 13:26, 2 November 2023 view source Alexander Berchansky (talk \| contribs) 29,726 edits No edit summary ← Older edit		Latest revision as of 09:46, 21 January 2024 view source Michal Harel (talk \| contribs) 32,820 edits No edit summary
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='~~Caption for this structure~~' scene='10/1004490/Cv/2'>		<StructureSection load='' size='340' side='right' caption='Ribociclib' scene='10/1004490/Cv/2'>
	Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4\|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).<ref name="a7">[https://www.hcp.novartis.com/products/kisqali/metastatic-breast-cancer/ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.]</ref> See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]].		Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4\|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6).<ref name="a7">[https://www.hcp.novartis.com/products/kisqali/metastatic-breast-cancer/ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.]</ref> See also [https://en.wikipedia.org/wiki/Ribociclib Ribociclib] and [[CDK4]].

Navigation menu